BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-88@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: AbbVie — Mirvetuximab soravtansine plus Bevacizumab [Apr
  2027]
DESCRIPTION:Phase 3 primary completion: Mirvetuximab Soravtansine With Beva
 cizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial
  Ovarian\, Fallopian Tube\, or Peritoneal Cancer.\nSource: https://clinica
 ltrials.gov/study/NCT05445778\nhttps://catalystbrief.girapphe.com/e/88?lan
 g=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/88?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
